Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterised by
worsening respiratory symptoms and physiological impairment. Increasing awareness of the …

Background No therapies are currently approved for the treatment of pulmonary
hypertension in patients with interstitial lung disease. The safety and efficacy of inhaled …

Guidelines summarize and evaluate available evidence, with the aim of assisting health
professionals in proposing the best management strategies for an individual patient with a …

Background: The presence of emphysema is relatively common in patients with fibrotic
interstitial lung disease. This has been designated combined pulmonary fibrosis and …

Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that
are often progressive and associated with high morbidity and early mortality. Important …

The pulmonary vasculature has been frequently overlooked in acute and chronic lung
diseases, such as acute respiratory distress syndrome (ARDS), pulmonary fibrosis (PF), and …

The discovery of soluble GC (sGC) stimulators and sGC activators provided valuable tools to
elucidate NO–sGC signalling and opened novel pharmacological opportunities for …

Cyclic guanosine monophosphate (cGMP) is a unique second messenger molecule formed
in different cell types and tissues. cGMP targets a variety of downstream effector molecules …

Pulmonary hypertension encompasses a range of conditions directly or indirectly leading to
elevated pressures within the pulmonary arteries. Five main groups of pulmonary …